We acknowledge the significance and value of ongoing innovation in diabetes.

In honor of the 100th anniversary of insulin, ATTD will award a prize supported by Eli Lilly to a practice/innovative way of managing diabetes.

Submit your nominee in the form below by 1 February 2023

• Today, 61 million people live with diabetes in Europe. The number of PwD is expected to rise to 69 million by 2045, which means that, by then, 1 in 10 Europeans could be living with diabetes⁽¹⁾.
• 75% of these costs are related to diabetes complications that are preventable with proper treatment⁽²⁾. Out of the total diabetes costs in the Big EU 5 in 2012, the percentage spent on insulin and anti-diabetic medicines ranged between 6% and 11%⁽³⁾.
• Every 6 seconds, a PwD dies because of a diabetes-related complication⁽⁴⁾.
• Only 50% of PwD reach the appropriate blood sugar levels for the condition (HBA1C <7.0%).

Reasons for outcomes non improving are strong conservatism, clinical inertia and treat-to fail paradigm.

• According to the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) consensus algorithm^(5-6), 30–60% of people with type 2 diabetes would qualify for more effective treatment⁽⁷⁾. However, in clinical reality, the percentage of PwD receiving more effective treatment remains very low, ranging between 1% and 10%⁽⁸⁾.
• Inertia for HCP is the recurring failure to establish appropriate targets and escalate treatment to achieve treatment goals ⁽⁹⁾, but also the behaviour to not setting clear goals or insufficient focus on goal attainment ^(10,11), or inadequate time/personnel to teach injectable therapy^(10,11).

We need to modernize diabetes care.